UVA Health Infectious Diseases Clinic
Welcome,         Profile    Billing    Logout  
 2 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schmid, Andreas
NCT05755932: Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Vs. HFA MDI Propellant in Healthy Participants

Completed
3
35
Europe, US
HFO MDI, Propellant in MDI, HFA MDI
AstraZeneca
Mucociliary Clearance
07/24
07/24
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Terminated
2
8
Europe, US, RoW
Itraconazole Powder, PUR1900, Placebo
Pulmatrix Inc., Pulmatrix, Inc.
ABPA
02/24
02/24
NCT06364176: Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Recruiting
2
42
US
Losartan, Placebo
University of Kansas Medical Center
Cystic Fibrosis
05/27
10/27
NCT04530383: Effects of Metformin on Airway Ion Channel Dysfunction in Cystic Fibrosis-related Diabetes

Recruiting
2
36
US
Metformin Hydrochloride, Glucophage
University of Kansas Medical Center
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
11/25
04/26
NCT02026375: Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers

Recruiting
N/A
30
US
fluticasone propionate, Flovent, placebo
University of Miami
Smokers
02/15
06/15
REBECCA, NCT05784480: Relevance of Reversible Causes During OHCA (Rebecca Study)

Recruiting
N/A
100
Europe
Checklist for evaluation of reversible causes, Venipuncture for toxicological screening, Point-of-Care blood gas analysis, Point-of-Care saliva toxicological screen, Point-of-care ultrasound
Medical University of Vienna, Seibersdorf Labor GmbH, Ludwig Boltzmann Institute for Digital Health and Prevention
Out-Of-Hospital Cardiac Arrest, Cardiopulmonary Arrest
04/25
12/25
Boccardi, Luigi
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
VIPAH-PRN 2B, NCT04266197: Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

Active, not recruiting
2
42
US
Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI), inhaled vardenafil
Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
11/24
12/24
NCT04568148: COVID-19 Biorepository

Active, not recruiting
N/A
201
US
University of Kansas Medical Center
Covid-19, SARS-CoV 2, Coronavirus, COVID
12/23
12/25
PHBR, NCT04808596: Pulmonary Hypertension Biorepository and Registry

Recruiting
N/A
300
US
University of Kansas Medical Center
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
12/26
07/27
NCT04885504: Post COVID-19 Biorepository

Recruiting
N/A
100
US
University of Kansas Medical Center
Coronavirus Infection
12/25
07/26
NCT04979767: Function of Circulating Exosomes in Sepsis-induced Immunosuppression

Recruiting
N/A
80
US
University of Kansas Medical Center, University of Kansas
Sepsis, Septic Shock, Sepsis Syndrome, Sepsis Bacterial, Sepsis, Severe, Sepsis Bacteremia
10/21
06/22
PIBR, NCT05530408: Quantitative Pulmonary Imaging Registry & Biorepository

Recruiting
N/A
100
US
University of Kansas Medical Center
Pulmonary Disease
12/27
05/28
Benkhadra, Hiba
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Riehm, Amy
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Farhat, Maha
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schmid, Andreas
NCT05755932: Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Vs. HFA MDI Propellant in Healthy Participants

Completed
3
35
Europe, US
HFO MDI, Propellant in MDI, HFA MDI
AstraZeneca
Mucociliary Clearance
07/24
07/24
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Terminated
2
8
Europe, US, RoW
Itraconazole Powder, PUR1900, Placebo
Pulmatrix Inc., Pulmatrix, Inc.
ABPA
02/24
02/24
NCT06364176: Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Recruiting
2
42
US
Losartan, Placebo
University of Kansas Medical Center
Cystic Fibrosis
05/27
10/27
NCT04530383: Effects of Metformin on Airway Ion Channel Dysfunction in Cystic Fibrosis-related Diabetes

Recruiting
2
36
US
Metformin Hydrochloride, Glucophage
University of Kansas Medical Center
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
11/25
04/26
NCT02026375: Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers

Recruiting
N/A
30
US
fluticasone propionate, Flovent, placebo
University of Miami
Smokers
02/15
06/15
REBECCA, NCT05784480: Relevance of Reversible Causes During OHCA (Rebecca Study)

Recruiting
N/A
100
Europe
Checklist for evaluation of reversible causes, Venipuncture for toxicological screening, Point-of-Care blood gas analysis, Point-of-Care saliva toxicological screen, Point-of-care ultrasound
Medical University of Vienna, Seibersdorf Labor GmbH, Ludwig Boltzmann Institute for Digital Health and Prevention
Out-Of-Hospital Cardiac Arrest, Cardiopulmonary Arrest
04/25
12/25
Boccardi, Luigi
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
VIPAH-PRN 2B, NCT04266197: Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

Active, not recruiting
2
42
US
Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI), inhaled vardenafil
Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
11/24
12/24
NCT04568148: COVID-19 Biorepository

Active, not recruiting
N/A
201
US
University of Kansas Medical Center
Covid-19, SARS-CoV 2, Coronavirus, COVID
12/23
12/25
PHBR, NCT04808596: Pulmonary Hypertension Biorepository and Registry

Recruiting
N/A
300
US
University of Kansas Medical Center
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
12/26
07/27
NCT04885504: Post COVID-19 Biorepository

Recruiting
N/A
100
US
University of Kansas Medical Center
Coronavirus Infection
12/25
07/26
NCT04979767: Function of Circulating Exosomes in Sepsis-induced Immunosuppression

Recruiting
N/A
80
US
University of Kansas Medical Center, University of Kansas
Sepsis, Septic Shock, Sepsis Syndrome, Sepsis Bacterial, Sepsis, Severe, Sepsis Bacteremia
10/21
06/22
PIBR, NCT05530408: Quantitative Pulmonary Imaging Registry & Biorepository

Recruiting
N/A
100
US
University of Kansas Medical Center
Pulmonary Disease
12/27
05/28
Benkhadra, Hiba
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Riehm, Amy
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Farhat, Maha
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28

Download Options